Vallée Jean-Noël, Paques Michel, Aymard Armand, Massin Pascale, Santiago Pierre-Yves, Adeleine Patrice, Gaudric Alain, Merland Jean-Jacques
Department of Neuroradiology, Hôpital Lariboisière, University of Paris, France.
Radiology. 2002 May;223(2):351-9. doi: 10.1148/radiol.2232010423.
To investigate the role of urokinase selectively perfused into the ophthalmic artery as an emergency treatment for combined central retinal arterial obstruction (CRAO) and central retinal venous obstruction (CRVO).
Over a 6-year period, 11 consecutive patients presented with recent combined CRAO and CRVO (< or =72 hours). Urokinase (300,000 IU) was selectively perfused via the femoral artery into the ophthalmic artery for 40 minutes. Evaluation criteria were Snellen visual acuity with best correction, funduscopic results, and retinal arteriovenous transit time assessed over a mean 3.5-year follow-up. Mean vision and retinal perfusion were tested by means of repeated-measures analysis of variance. The correlation between visual improvement and retinal perfusion improvement was evaluated by means of Spearman rank correlation.
Substantial improvement in vision and retinal perfusion was noted in seven of the 11 patients treated. Mean vision improvement was significant (P =.009) within 24-48 hours after fibrinolysis, increased until 1 month after (P =.006), then remained stable throughout the follow-up (P >.10). Visual improvement correlated with retinal perfusion improvement during the period from before fibrinolysis to 24-48 hours after (P =.028). In all patients with improved results, retinal hemorrhages transiently increased. One patient had intravitreal hemorrhage shortly after fibrinolysis.
For this uncommon clinical entity, which typically has a poor visual outcome, these results suggest that ophthalmic arterial fibrinolysis may restore retinal perfusion, which leads to rapid substantial visual improvement in many cases of combined CRAO and CRVO, without systemic complications, but it may be responsible for intravitreal hemorrhage.
探讨经眼动脉选择性灌注尿激酶作为视网膜中央动脉阻塞(CRAO)合并视网膜中央静脉阻塞(CRVO)急诊治疗方法的作用。
在6年期间,连续11例患者近期出现CRAO合并CRVO(≤72小时)。通过股动脉将尿激酶(300,000国际单位)选择性灌注至眼动脉40分钟。评估标准包括最佳矫正视力、眼底检查结果以及在平均3.5年随访期间评估的视网膜动静脉通过时间。采用重复测量方差分析测试平均视力和视网膜灌注。通过Spearman等级相关性评估视力改善与视网膜灌注改善之间的相关性。
在接受治疗的11例患者中,7例视力和视网膜灌注有显著改善。溶栓后24 - 48小时内平均视力改善显著(P = 0.009),至1个月时增加(P = 0.006),随后在整个随访期间保持稳定(P > 0.10)。从溶栓前到溶栓后24 - 48小时期间,视力改善与视网膜灌注改善相关(P = 0.028)。在所有结果改善的患者中,视网膜出血短暂增加。1例患者在溶栓后不久发生玻璃体积血。
对于这种通常视力预后较差的罕见临床病症,这些结果表明眼动脉溶栓可能恢复视网膜灌注,这在许多CRAO合并CRVO病例中可导致视力迅速显著改善,且无全身并发症,但可能导致玻璃体积血。